DDrare: Database of Drug Development for Rare Diseases

Searched query = "Addison disease", "Primary chronic adrenocortical insufficiency", "Autoimmune polyglandular syndrome", "Hypoparathyroidism-Addison-Monilia syndrome", "HAM syndrome", "Schmidt syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; Cortef; Cortef (hydrocortisone); Cortef 5 mg; Cosyntropin; Dehydroepiandrosterone; Depot tetracosactide; Device: 30-hour ambulatory sampling of intestinal fluid; Dexamethasone; Diagnostic Test: Baseline blood tests; Diagnostic Test: Cosyntropin stimulation test; Grapefruit; Grapefruit Juice; HYDROCORTISONE HYDROGEN SUCCINATE; HYDROCORTISONE ROUSSEL; HYDROCORTISONE SODIUM SUCCINATE; Hydrocortison 100 mg (Pfizer®) in 2 ml solvent; Hydrocortisone; Hydrocortisone 100mg/ml; Hydrocortisone Roussel; Hydrocortisone hydrogen succinate; Hydrocortisone sodium phosphate; Hydrocortisonum; Hydrogen; Hydrokortison APL kapsel 2,5 mg; Isocaloric Diet; Liquorice; MabThera; Mabthera Infusion; Mabthera infusion; Medrone; Methylprednisolone; Phosphate; Rituximab; Solu-Cortef; Solu-Cortef (hydrocortisone); Solu-Medrone; Solu-cortef; Solu-medrone; Synacthen Depot; Tetracosactide; Tetracosactide acetate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-002687-25-DE (EUCTR)	16/11/2011	06/10/2011	Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of hydrocortisone, after subcutaneous injection in patients with chronic primary adrenal insufficiency(Comparison s.c. vs. i.m.)	Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency(PHYSCA-Trial) - PHYSCA- Trial	Adrenal insufficiency under chronic glucocorticoid replacement MedDRA version: 14.0;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.0;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Hydrocortison 100 mg (Pfizer®) in 2 ml solvent INN or Proposed INN: Hydrocortisone Other descriptive name: HYDROCORTISONE HYDROGEN SUCCINATE	University Hospital of Wuerzburg	NULL	Not Recruiting			Female: yes Male: yes	12		Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-002687-25-DE
(EUCTR)

16/11/2011

06/10/2011

Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of hydrocortisone, after subcutaneous injection in patients with chronic primary adrenal insufficiency(Comparison s.c. vs. i.m.)

Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency(PHYSCA-Trial) - PHYSCA- Trial

Adrenal insufficiency under chronic glucocorticoid replacement
MedDRA version: 14.0;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: Hydrocortison 100 mg (Pfizer®) in 2 ml solvent
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE HYDROGEN SUCCINATE

University Hospital of Wuerzburg

NULL

Not Recruiting

Female: yes
Male: yes

Germany